News

Talphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financing
Discover key takeaways from Talphera's Q1 2025 Earnings Call! Learn about FDA protocol changes, financial updates, and progress on the NEPHRO CRRT study.